➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
AstraZeneca
McKinsey
Boehringer Ingelheim
Merck

Last Updated: January 27, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for NOVA-22007

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug NOVA-22007?

NOVA-22007 is an investigational drug.

There have been 26 clinical trials for NOVA-22007. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2017.

The most common disease conditions in clinical trials are Disease, Diabetes Mellitus, and Schizophrenia. The leading clinical trial sponsors are Nova Scotia Health Authority, Canadian Institutes of Health Research (CIHR), and Canadian Network for Observational Drug Effect Studies, CNODES.

There are two US patents protecting this investigational drug and forty-three international patents.

Recent Clinical Trials for NOVA-22007
TitleSponsorPhase
The ACTS Trial: N-acetylcysteine (NAC) and Night-splinting as a Non-operative Treatment for Carpal Tunnel SyndromeDavid TangPhase 4
Psychological Therapy for Psychosis, Adverse Events, and Substance MisuseKillam LaureatesN/A
Psychological Therapy for Psychosis, Adverse Events, and Substance MisuseQueen Elizabeth II Health Sciences Centre FoundationN/A

See all NOVA-22007 clinical trials

Clinical Trial Summary for NOVA-22007

Top disease conditions for NOVA-22007
Top clinical trial sponsors for NOVA-22007

See all NOVA-22007 clinical trials

US Patents for NOVA-22007

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
NOVA-22007   Start Trial Fused bicyclic heteroaromatic derivatives as kinase inhibitors UCB BIOPHARMA SPRL (Brussels, BY) KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (Leuven, BE)   Start Trial
NOVA-22007   Start Trial Methods for determining risk of chronic lung allograft dysfunction (CLAD) and subtypes thereof University Health Network (Toronto, CA)   Start Trial
NOVA-22007   Start Trial Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR)   Start Trial
NOVA-22007   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
NOVA-22007   Start Trial Salts of an epidermal growth factor receptor kinase inhibitor Celgene CAR LLC (Pembroke, BM)   Start Trial
NOVA-22007   Start Trial Methods of treating colorectal cancer Nogra Pharma Limited (Dublin, IE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for NOVA-22007

Drugname Country Document Number Estimated Expiration Related US Patent
NOVA-22007 Brazil BR112016029632 2034-06-17   Start Trial
NOVA-22007 Canada CA2951349 2034-06-17   Start Trial
NOVA-22007 China CN106559992 2034-06-17   Start Trial
NOVA-22007 European Patent Office EP3157924 2034-06-17   Start Trial
NOVA-22007 United Kingdom GB201410817 2034-06-17   Start Trial
NOVA-22007 Japan JP2017518385 2034-06-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
AstraZeneca
McKinsey
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.